Ionis Pharmaceuticals, Inc.
IONS
Peringkat dalam Saham
#2572
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Harga Saham
$44.84
Kapitalisasi Pasar
$7.45B
Perubahan (1 hari)
1.04%
Perubahan (1 tahun)
-39.03%
Negara
US
Perdagangan Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Rasio P/S untuk Ionis Pharmaceuticals, Inc. (IONS)
Rasio P/S per October 2026 TTM: 8.12
Menurut laporan keuangan dan harga saham terbaru dari Ionis Pharmaceuticals, Inc., rasio P/S saat ini (TTM) adalah 8.12. Pada akhir 2023, rasio P/S perusahaan adalah 9.18.
Riwayat rasio P/S untuk Ionis Pharmaceuticals, Inc. dari 2000 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 8.12 | 9.60% |
| 2024 | 7.41 | -19.29% |
| 2023 | 9.18 | 0.63% |
| 2022 | 9.13 | 72.28% |
| 2021 | 5.30 | -51.07% |
| 2020 | 10.83 | 43.78% |
| 2019 | 7.53 | -36.87% |
| 2018 | 11.93 | -2.92% |
| 2017 | 12.29 | -26.29% |
| 2016 | 16.67 | -35.99% |
| 2015 | 26.04 | -23.25% |
| 2014 | 33.93 | 13.51% |
| 2013 | 29.89 | 190.50% |
| 2012 | 10.29 | 41.89% |
| 2011 | 7.25 | -21.60% |
| 2010 | 9.25 | 3.19% |
| 2009 | 8.96 | -28.35% |
| 2008 | 12.51 | -33.96% |
| 2007 | 18.94 | -43.76% |
| 2006 | 33.68 | 310.28% |
| 2005 | 8.21 | 4.71% |
| 2004 | 7.84 | 8.72% |
| 2003 | 7.21 | 61.05% |
| 2002 | 4.48 | -75.63% |
| 2001 | 18.37 | 74.01% |
| 2000 | 10.56 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | 23.41% |
US
|
|
| 40.55 | 399.31% |
US
|
|
| 3.96 | -51.23% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 24.93% |
NL
|
